<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320904">
  <stage>Registered</stage>
  <submitdate>4/12/2009</submitdate>
  <approvaldate>8/12/2009</approvaldate>
  <actrnumber>ACTRN12609001046291</actrnumber>
  <trial_identification>
    <studytitle>A phase I randomised repeat dose study in healthy volunteers to determine the oral bioavailability of various formulations of vitamin D in combination with the novel penetration enhancer tocopheryl phosphate mix (TPM)</studytitle>
    <scientifictitle>A phase I randomised repeat dose study in healthy volunteers to test various oral formulations of vitamin D in combination with the novel penetration enhancer tocopheryl phosphate mix (TPM), in order to determine the amount of vitamin D that reaches the blood stream.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>No known secondary IDs</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>vitamin D deficiency</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Group 1- vitamin D in combination with tocopheryl phosphate mix (TPM) oil based, in a capsule form- administered orally, once a day for 28 days (concentration is 1000 IU, 25 mcg vitamin D and 2IU, 1.5 mg TPM)
Group 2- vitamin D in combination with tocopheryl phosphate mix (TPM) aqueous based, in a capsule form- administered orally, once a day for 28 days (concentration is 1000 IU, 25 mcg vitamin D and 2IU, 1.5 mg TPM)</interventions>
    <comparator>Group 3- vitamin D capsules, administered orally, once a day for 28 days (concentration 1000 IU, 25 mcg)

Group 4- vitamin D capsules, administered orally, once a day for 28 days (concentration 5000 IU, 125 mcg)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine if vitamin D/TPM formulations show improved bioavailability compared to vitamin D supplementation alone</outcome>
      <timepoint>Days 1, 2, 4, 7, 14, 21 and 28.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the safety and tolerability of various formulations of vitamin D.
Clinical Laboratory Testing</outcome>
      <timepoint>Days 1, 7 , 14, 28 and follow-up.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Male or Female aged 18 to 65 years (inclusive).
2. Healthy subjects - healthy subjects are defined as individuals who are free from clinically significant illness or disease as determine by their medical history.
3. Body Mass Index equal or greater than 18 and equal or less than 25 kg/m2.
4. Fluent in the English language.
5. Able to provide written informed consent to participate in the study and is willing to comply with the study procedures.
6. Non-smokers, or has quit at least 3 months prior to administration of the study treatment.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Pregnant or breastfeeding.
2. Individuals who smoked an average of one or more cigarette or tobacco form (including cigar) per month in the last 3 months.
3. Individuals with any current medical problems (current is defined as being within the last 3 months prior to administration of the study treatment).
4. Use of any medications or supplements within 14 days of administration of study treatment.
5. Use of any oral or topical vitamin D supplementation within 14 days of administration of study treatment.
6. Exposure to intense solar or artificial ultraviolet (UV)/tanning salons in the 3 months prior to administration of study treatment.
7. Unwilling or unable to avoid UV exposure for the duration of the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects will be randomly allocated to a study treatment via an online ‘randomising’ program (computer sequence generator).  Allocation is not concealed.</concealment>
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>31/01/2010</anticipatedstartdate>
    <actualstartdate>26/10/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>16/12/2010</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Phosphagenics Limited</primarysponsorname>
    <primarysponsoraddress>11 Duerdin Street
Clayton VIC
3168</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Phosphagenics Limited</fundingname>
      <fundingaddress>11 Duerdin Street
Clayton VIC
3168</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to see how much and how fast vitamin D is absorbed into the skin when combined with the penetration enhancer tocopheryl phosphate mix (TPM) and to then compare it to vitamin D alone.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Health Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>3/12/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Miss</title>
      <name>Yelda Ogru</name>
      <address>Phosphagenics Ltd
11 Duerdin St 
Clayton, 3168
VICTORIA
</address>
      <phone>61 3 9565 1156</phone>
      <fax />
      <email>yogru@phosphagenics.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Yelda Ogru</name>
      <address>Phosphagenics Ltd
Phosphagenics Ltd
11 Duerdin St 
Clayton, 3168
VICTORIA
</address>
      <phone>61 3 9565 1156</phone>
      <fax />
      <email>yogru@phosphagenics.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Yelda Ogru</name>
      <address>11 Duerdin Street
Clayton VIC
3168</address>
      <phone>61 3 9565 1156</phone>
      <fax />
      <email>yogru@phosphagenics.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Roksan Libinaki</name>
      <address>Phosphagenics Ltd
11 Duerdin St 
Clayton, 3168
VICTORIA
</address>
      <phone>+61 3 9565 1119</phone>
      <fax />
      <email>rlibinaki@phosphagenics.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>